MedPath

Otonomy, Inc.

Otonomy, Inc. logo
🇺🇸United States
Ownership
Private
Established
2008-01-01
Employees
51
Market Cap
-
Website
http://www.otonomy.com

A 6-Month Extension Study of OTO-104 in Meniere's Disease

Phase 3
Terminated
Conditions
Meniere's Disease
Interventions
First Posted Date
2016-03-11
Last Posted Date
2022-12-14
Lead Sponsor
Otonomy, Inc.
Target Recruit Count
189
Registration Number
NCT02706730
Locations
🇺🇸

Many sites in US. Refer to the contact info listed below., San Diego, California, United States

Study of OTO-104 in Subjects With Unilateral Meniere's Disease

Phase 3
Completed
Conditions
Meniere's Disease
Interventions
Drug: Placebo
First Posted Date
2015-11-23
Last Posted Date
2023-01-12
Lead Sponsor
Otonomy, Inc.
Target Recruit Count
166
Registration Number
NCT02612337
Locations
🇺🇸

Many sites in US. Refer to the contact info listed below., San Diego, California, United States

Open-Label Study of OTO-201 in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes

Phase 3
Completed
Conditions
Otitis Media
Interventions
Drug: OTO-201 (ciprofloxacin)
First Posted Date
2015-11-09
Last Posted Date
2020-10-19
Lead Sponsor
Otonomy, Inc.
Target Recruit Count
501
Registration Number
NCT02600559
Locations
🇺🇸

Email Otonomy Central Contact for Trial Locations, San Diego, California, United States

OTO-201 for the Treatment of Otitis Externa

Phase 2
Completed
Conditions
Otitis Externa
Interventions
Drug: OTO-201 (ciprofloxacin)
First Posted Date
2015-07-30
Last Posted Date
2020-10-19
Lead Sponsor
Otonomy, Inc.
Target Recruit Count
75
Registration Number
NCT02511561
Locations
🇺🇸

Email Otonomy Central Contact for Trial Locations, San Diego, California, United States

Open-Label Study of OTO-201 for Treatment of AOMT

Phase 2
Completed
Conditions
Acute Otitis Media
AOMT
Interventions
First Posted Date
2015-04-03
Last Posted Date
2020-10-19
Lead Sponsor
Otonomy, Inc.
Target Recruit Count
39
Registration Number
NCT02408796
Locations
🇺🇸

South Florida Pediatric Otolaryngology, Fort Lauderdale, Florida, United States

🇺🇸

Carolina Ear, Nose and Throat, Orangeburg, South Carolina, United States

🇺🇸

Central California Ear, Nose and Throat, Fresno, California, United States

and more 1 locations

Open-Label Study of OTO-201 for Middle Ear Effusion Evaluating Trans-Tympanostomy Tube Administration

Phase 3
Completed
Conditions
Bilateral Middle Ear Effusion
Interventions
First Posted Date
2015-01-30
Last Posted Date
2020-10-19
Lead Sponsor
Otonomy, Inc.
Target Recruit Count
33
Registration Number
NCT02350998
Locations
🇺🇸

Charlotte Eye, Ear, Nose and Throat Associates, Matthews, North Carolina, United States

🇺🇸

Central California Ear, Nose and Throat, Fresno, California, United States

🇺🇸

Piedmont Ear, Nose and Throat, Winston-Salem, North Carolina, United States

and more 1 locations

A 1-Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom

Phase 2
Completed
Conditions
Meniere's Disease
Interventions
Drug: Placebo
First Posted Date
2014-10-15
Last Posted Date
2017-08-18
Lead Sponsor
Otonomy, Inc.
Target Recruit Count
128
Registration Number
NCT02265393
Locations
🇬🇧

Oxford University Hospitals, Bucks, United Kingdom

🇬🇧

BMI The Edgbaston Hospital, Birmingham, United Kingdom

🇬🇧

Leicester Royal Infirmary, Leicestershire, United Kingdom

and more 12 locations

OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement

Phase 3
Completed
Conditions
Otitis Media With Effusion
Interventions
Drug: Sham
First Posted Date
2013-09-24
Last Posted Date
2016-11-11
Lead Sponsor
Otonomy, Inc.
Target Recruit Count
266
Registration Number
NCT01949155
Locations
🇺🇸

Call/email Otonomy Central Contact for Trial Locations, San Diego, California, United States

OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement

Phase 3
Completed
Conditions
Otitis Media With Effusion
Interventions
Drug: Sham
First Posted Date
2013-09-24
Last Posted Date
2016-06-15
Lead Sponsor
Otonomy, Inc.
Target Recruit Count
266
Registration Number
NCT01949142
Locations
🇺🇸

Call/email Otonomy Central Contact for Trial Locations, San Diego, California, United States

OTO-201 for Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement

Phase 1
Completed
Conditions
Bilateral Middle Ear Effusion Requiring Tympanostomy Tube Placement
Interventions
Drug: Placebo
Drug: Sham
First Posted Date
2012-12-24
Last Posted Date
2013-06-19
Lead Sponsor
Otonomy, Inc.
Target Recruit Count
83
Registration Number
NCT01755286
Locations
🇺🇸

Call/Email Otonomy Central Contact for Trial Locations, San Diego, California, United States

© Copyright 2025. All Rights Reserved by MedPath